Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ)
CNY 6.88
(-1.01%)
CNY 6.88
(-1.01%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 533.23 Million CNY | -19.11% |
| 2022 | 659.19 Million CNY | 14.7% |
| 2021 | 574.71 Million CNY | 5.5% |
| 2020 | 544.72 Million CNY | 8.84% |
| 2019 | 500.5 Million CNY | -6.79% |
| 2018 | 536.98 Million CNY | 14.72% |
| 2017 | 468.08 Million CNY | 4.03% |
| 2016 | 449.95 Million CNY | -5.43% |
| 2015 | 475.8 Million CNY | -15.91% |
| 2014 | 565.82 Million CNY | 149.54% |
| 2013 | 226.74 Million CNY | 117.04% |
| 2012 | 104.47 Million CNY | 21.6% |
| 2011 | 85.91 Million CNY | 14.17% |
| 2010 | 75.24 Million CNY | 20.72% |
| 2009 | 62.33 Million CNY | -6.05% |
| 2008 | 66.34 Million CNY | 2.73% |
| 2007 | 64.58 Million CNY | 3.05% |
| 2006 | 62.67 Million CNY | 15.31% |
| 2005 | 54.34 Million CNY | 45.08% |
| 2004 | 37.45 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 77.86 Million CNY | -9.23% |
| 2024 Q1 | 94.41 Million CNY | -39.48% |
| 2024 Q2 | 85.78 Million CNY | -9.14% |
| 2023 Q4 | 156 Million CNY | 30.2% |
| 2023 Q1 | 128.49 Million CNY | -47.46% |
| 2023 FY | 533.23 Million CNY | -19.11% |
| 2023 Q2 | 128.91 Million CNY | 0.33% |
| 2023 Q3 | 119.81 Million CNY | -7.06% |
| 2022 Q1 | 120.58 Million CNY | -29.87% |
| 2022 Q4 | 244.58 Million CNY | 45.79% |
| 2022 Q3 | 167.76 Million CNY | 32.87% |
| 2022 FY | 659.19 Million CNY | 14.7% |
| 2022 Q2 | 126.26 Million CNY | 4.71% |
| 2021 Q1 | 121.97 Million CNY | -35.54% |
| 2021 Q3 | 150.49 Million CNY | 15.49% |
| 2021 Q4 | 171.94 Million CNY | 14.25% |
| 2021 FY | 574.71 Million CNY | 5.5% |
| 2021 Q2 | 130.3 Million CNY | 6.83% |
| 2020 FY | 544.72 Million CNY | 8.84% |
| 2020 Q2 | 115.86 Million CNY | 25.42% |
| 2020 Q1 | 92.38 Million CNY | -43.11% |
| 2020 Q4 | 189.22 Million CNY | 28.51% |
| 2020 Q3 | 147.24 Million CNY | 27.09% |
| 2019 Q3 | 123.51 Million CNY | -2.61% |
| 2019 Q2 | 126.82 Million CNY | 44.49% |
| 2019 Q1 | 87.77 Million CNY | -56.54% |
| 2019 Q4 | 162.39 Million CNY | 31.47% |
| 2019 FY | 500.5 Million CNY | -6.79% |
| 2018 Q3 | 121.69 Million CNY | 1.5% |
| 2018 Q1 | 93.43 Million CNY | -46.5% |
| 2018 Q2 | 119.89 Million CNY | 28.33% |
| 2018 FY | 536.98 Million CNY | 14.72% |
| 2018 Q4 | 201.96 Million CNY | 65.96% |
| 2017 Q1 | 78.46 Million CNY | -55.23% |
| 2017 FY | 468.08 Million CNY | 4.03% |
| 2017 Q4 | 174.64 Million CNY | 63.71% |
| 2017 Q3 | 106.68 Million CNY | -1.49% |
| 2017 Q2 | 108.29 Million CNY | 38.02% |
| 2016 FY | 449.95 Million CNY | -5.43% |
| 2016 Q1 | 73.4 Million CNY | -53.3% |
| 2016 Q2 | 92.7 Million CNY | 26.31% |
| 2016 Q4 | 175.25 Million CNY | 61.39% |
| 2016 Q3 | 108.58 Million CNY | 17.13% |
| 2015 FY | 475.8 Million CNY | -15.91% |
| 2015 Q4 | 157.16 Million CNY | 60.04% |
| 2015 Q3 | 98.2 Million CNY | -15.65% |
| 2015 Q2 | 116.43 Million CNY | 11.96% |
| 2015 Q1 | 103.99 Million CNY | -39.15% |
| 2014 Q3 | 132.45 Million CNY | -2.77% |
| 2014 Q4 | 170.89 Million CNY | 29.02% |
| 2014 Q1 | 126.23 Million CNY | -5.71% |
| 2014 FY | 565.82 Million CNY | 149.54% |
| 2014 Q2 | 136.23 Million CNY | 7.92% |
| 2013 Q3 | 31.45 Million CNY | -1.04% |
| 2013 Q4 | 133.88 Million CNY | 325.58% |
| 2013 FY | 226.74 Million CNY | 117.04% |
| 2013 Q1 | 29.6 Million CNY | -8.04% |
| 2013 Q2 | 31.79 Million CNY | 7.37% |
| 2012 Q4 | 32.19 Million CNY | 23.51% |
| 2012 Q1 | 22.08 Million CNY | -31.75% |
| 2012 Q3 | 26.07 Million CNY | 8.11% |
| 2012 FY | 104.47 Million CNY | 21.6% |
| 2012 Q2 | 24.11 Million CNY | 9.18% |
| 2011 Q2 | 11.39 Million CNY | -54.6% |
| 2011 Q4 | 32.36 Million CNY | 89.8% |
| 2011 Q3 | 17.04 Million CNY | 49.58% |
| 2011 Q1 | 25.1 Million CNY | 9.54% |
| 2011 FY | 85.91 Million CNY | 14.17% |
| 2010 Q2 | 23.1 Million CNY | 45.15% |
| 2010 FY | 75.24 Million CNY | 20.72% |
| 2010 Q3 | 13.3 Million CNY | -42.41% |
| 2010 Q1 | 15.91 Million CNY | -18.37% |
| 2010 Q4 | 22.91 Million CNY | 72.21% |
| 2009 Q2 | 15 Million CNY | 5.36% |
| 2009 Q3 | 13.58 Million CNY | -9.49% |
| 2009 Q4 | 19.5 Million CNY | 43.58% |
| 2009 FY | 62.33 Million CNY | -6.05% |
| 2009 Q1 | 14.24 Million CNY | -31.24% |
| 2008 Q4 | 20.71 Million CNY | 30.38% |
| 2008 Q2 | 14.47 Million CNY | -5.22% |
| 2008 Q1 | 15.27 Million CNY | -25.75% |
| 2008 FY | 66.34 Million CNY | 2.73% |
| 2008 Q3 | 15.88 Million CNY | 9.76% |
| 2007 FY | 64.58 Million CNY | 3.05% |
| 2007 Q2 | 16.13 Million CNY | 24.49% |
| 2007 Q1 | 12.95 Million CNY | -44.73% |
| 2007 Q3 | 14.92 Million CNY | -7.47% |
| 2007 Q4 | 20.56 Million CNY | 37.79% |
| 2006 Q3 | 14.44 Million CNY | 0.0% |
| 2006 Q4 | 23.44 Million CNY | 62.25% |
| 2006 FY | 62.67 Million CNY | 15.31% |
| 2005 FY | 54.34 Million CNY | 45.08% |
| 2004 FY | 37.45 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 32.05 Billion CNY | 98.336% |
| Zhejiang Zhenyuan Share Co., Ltd. | 4.1 Billion CNY | 87.014% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 656.89 Million CNY | 18.825% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 737.81 Million CNY | 27.729% |
| Yifan Pharmaceutical Co., Ltd. | 4.02 Billion CNY | 86.743% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 21.15 Billion CNY | 97.479% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 895.59 Million CNY | 40.46% |
| Boai NKY Medical Holdings Ltd. | 1.58 Billion CNY | 66.324% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 848.19 Million CNY | 37.133% |